Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis (ReaSoN-IPF/PPF)
A Prospective, Multicenter, Observational Real-world Study of Nerandomilast Efficacy and Safety in Patients With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
Nerandomilast is an oral medicine that slows down the loss of functional residual capacity (FVC) in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It was tested in two large clinical trials in which participants were carefully selected. In everyday practice, patients are often older, have more other illnesses, or take additional medicines, and it is not known whether the benefits seen in the trials also occur outside them.
The Real-world Study of Nerandomilast (ReaSoN-IPF/PPF) follows people with IPF or PPF who begin nerandomilast as part of their usual medical care at several medical centers in Israel. The study does not assign any treatment; the treating physician makes every decision about therapy.
The main goal is to find out whether lung function declines more slowly once nerandomilast is started. Because patients have breathing tests before they begin the medicine as well as during treatment, each patient is compared with themselves: the rate at which their FVC was declining beforehand is compared with the rate following treatment.
The study also asks how patients feel, using a questionnaire called the K-BILD, and records side effects, hospital admissions, disease exacerbations, and whether patients stop the medicine.
Participants attend their normal clinic visits. They complete the questionnaire before treatment starts and again at 6 to 12 months, and their routine lung function results are collected. No extra tests or visits are required beyond the questionnaire.
연구 개요
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Doron Cohn-Schwartz, MD, PhD
- 전화번호: 972-3-6973591
- 이메일: doroncs@tlvmc.gov.il
연구 연락처 백업
- 이름: Avraham Unterman, MD, MBA
- 전화번호: 972-3-6973591
- 이메일: ramiu@tlvmc.gov.il
연구 장소
-
-
-
Ashkelon, 이스라엘, 7830604
- 모병
- Barzilai Medical Center, Ben-Gurion University of the Negev
-
연락하다:
- Ori Wand, MD
- 전화번호: 972-8-6745465
- 이메일: oriw@bmc.gov.il
-
Haifa, 이스라엘, 3109601
- 모병
- Rambam Health Care Campus, Technion - Israel Institute of Technology
-
연락하다:
- Yaniv Dotan, MD, PhD
- 전화번호: 972-4-8542648
- 이메일: Y_dotan@rmc.gov.il
-
Ramat Gan, 이스라엘, 5265601
- 모병
- Sheba Medical Center, Tel-HaShomer, Tel-Aviv University
-
연락하다:
- Liran Levy, MD
- 전화번호: 972-3-5302745
- 이메일: Liran.Levy@sheba.health.gov.il
-
Tel Aviv, 이스라엘, 6423906
- 모병
- Tel-Aviv Sourasky University Medical Center, Tel-Aviv University
-
연락하다:
- Doron Cohn-Schwartz, MD, PhD
- 전화번호: 972-3-6973591
- 이메일: doroncs@tlvmc.gov.il
-
연락하다:
- Avraham Unterman, MD, MBA
- 전화번호: 972-3-6973591
- 이메일: ramiu@tlvmc.gov.il
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Consecutive adults with IPF or PPF followed at one of the participating medical centers who initiate nerandomilast as part of routine clinical care during the enrollment period. Since this is a registry-based study, patients need to be included in a prospective ILD registry in order to participate.
설명
Inclusion Criteria:
- Age 18 years or older.
- Physician-confirmed diagnosis of IPF according to current ATS/ERS/JRS/ALAT guidelines, or of PPF (fibrotic interstitial lung disease other than IPF meeting INBUILD criteria for progression).
- Initiating treatment with nerandomilast as part of routine clinical care, with the treatment decision made independently of, and prior to, study enrollment.
- Willing and able to provides written informed consent to participate in the prospective ILD registry of the respective medical center.
Exclusion Criteria:
- Prior exposure to nerandomilast, including in a clinical trial or open-label extension study.
- Concurrent participation in an interventional trial of an investigational agent for interstitial lung disease.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
IPF or PPF
Patients who are diagnosed with IPF |
Either Nerandomilast 9mg twice a day or 18mg twice a day |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Adverse events
기간: Through study completion, an average of 9 months
|
Proportion of participants experiencing prespecified adverse events (diarrhea, weight loss, nausea, cough, upper respiratory tract infection, dyspnea, nasopharyngitis, worsening of underlying condition, depression, anxiety), reported overall and by severity. |
Through study completion, an average of 9 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Difference between the pre-treatment and on-treatment annualized rate of FVC decline (mL/year)
기간: Up to 24 months before initiation and, on average, 6 months after initiation
|
Average for all participants. For each participant, the annualized slope of absolute forced vital capacity over the period preceding nerandomilast initiation (derived from at least two pre-treatment measurements obtained within the previous 24 months) is compared with the annualized slope during 12 months of treatment. Each participant serves as their own control; the outcome is the within-participant difference between the two slopes, in mL/year, with a positive value indicating attenuation of decline on treatment. |
Up to 24 months before initiation and, on average, 6 months after initiation
|
|
Difference between pre-treatment and on-treatment annualized rate of FVC decline (% predicted/year)
기간: Up to 24 months before initiation and, on average, 6 months after initiation
|
As for outcome 2, with FVC expressed as percentage of predicted value. |
Up to 24 months before initiation and, on average, 6 months after initiation
|
|
Difference between pre-treatment and on-treatment annualized rate of DLCO decline (% predicted/year)
기간: Up to 24 months before initiation and, on average, 6 months after initiation
|
As above, for diffusing capacity of the lungs for carbon monoxide, corrected for hemoglobin. |
Up to 24 months before initiation and, on average, 6 months after initiation
|
|
Change from baseline in K-BILD domain scores
기간: Baseline and 6-12 months
|
Breathlessness and activities, psychological, and chest symptoms domains, each scored 0-100, higher indicating better health status. |
Baseline and 6-12 months
|
|
Change from baseline in FVC (mL and % predicted)
기간: Baseline and >6 months
|
Absolute annualized change in forced vital capacity from the pre-treatment baseline measurement. |
Baseline and >6 months
|
|
Change from baseline in DLCO (% predicted)
기간: Baseline and >6 months
|
Absolute annualized change in hemoglobin-corrected diffusing capacity from the pre-treatment baseline measurement. |
Baseline and >6 months
|
|
Incidence of serious adverse events
기간: Through study completion, an average of 9 months
|
Proportion of participants with at least one serious adverse event, defined as an event that is fatal, life-threatening, requires or prolongs hospitalization, or results in persistent or clinically significant disability. |
Through study completion, an average of 9 months
|
|
Permanent discontinuation of nerandomilast
기간: Through study completion, an average of 9 months
|
Proportion of participants permanently discontinuing nerandomilast, time to discontinuation, and reason for discontinuation. |
Through study completion, an average of 9 months
|
|
Dose reduction of nerandomilast
기간: Through study completion, an average of 9 months
|
Proportion of participants in whom nerandomilast dose is reduced, time to dose reduction, and reason for dose reduction. |
Through study completion, an average of 9 months
|
|
Annualized incidence of acute exacerbation of interstitial lung disease
기간: Through study completion, an average of 9 months
|
Number and proportion of participants with at least one acute exacerbation, defined according to published criteria, time to exacerbation. |
Through study completion, an average of 9 months
|
|
Annualized incidence of respiratory-cause hospitalization
기간: Through study completion, an average of 9 months
|
Annualized incidence of respiratory-cause hospitalization |
Through study completion, an average of 9 months
|
|
Annualized all-cause mortality
기간: Through study completion, an average of 9 months
|
Proportion of participants who die from any cause during follow-up. |
Through study completion, an average of 9 months
|
|
Annualized incidence of lung transplantation
기간: Through study completion, an average of 9 months
|
Proportion of participants undergoing lung transplantation during follow-up. |
Through study completion, an average of 9 months
|
|
Exploratory: Outcomes stratified by diagnosis, nerandomilast dosage, and background antifibrotic therapy
기간: Through study completion, an average of 9 months
|
Primary and key secondary outcomes reported separately for IPF versus PPF, and for background nintedanib, pirfenidone, or no background antifibrotic therapy. |
Through study completion, an average of 9 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 0101-21-TLV-A
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .